fcmedicineФундаментальная и клиническая медицинаFundamental and Clinical Medicine2500-07642542-0941КемГМУfcmedicine-75Research ArticleСтатьиСРАВНЕНИЕ БЕЛКОВОГО СОСТАВА ЭКСТРАЦЕЛЛЮЛЯРНОГО МАТРИКСА ПЕЧЕНОЧНЫХ МЕТАСТАЗОВ КОЛОРЕКТАЛЬНОГО РАКА И НОРМАЛЬНЫХ ТКАНЕЙ ПЕЧЕНИPROTEOMIC COMPARISON OF EXTRACELLULAR MATRIX WITHIN LIVER METASTASES OF COLORECTAL CANCER AND NORMAL LIVERЮжалинА. Е.YuzhalinARSENIY E.noemail@neicon.ruМушелР. Ж.MuschelRUTH J.noemail@neicon.ruКафедра онкологии, Оксфордский институт радиационной онкологии, Оксфордский университетРоссияCRUK/MRC Oxford Institute for Radiation OncologyRussian Federation201830032018311621Copyright © Южалин А.Е., Мушел Р.Ж., 20182018Южалин А.Е., Мушел Р.Ж.Yuzhalin A.E., Muschel R.J.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://fcm.kemsmu.ru/jour/article/view/75

Цель. Сравнить состав белков экстрацеллюлярного матрикса в индуцированных in vivo печеночных метастазах колоректального рака и нормальных тканях печени. Материалы и методы. Экстрацеллюлярный матрикс выделялся посредством децеллюляризации с использованием коктейля детергентов. Белковый состав печеночных метастазов колоректального рака и нормальных тканей печени исследовался при помощи масс-спектрометрии и иммунофлюоресцентного окрашивания. Результаты. Протеомный анализ выявил значительные различия в экспрессии белков экстрацеллюлярного матрикса между печеночными метастазами колоректального рака и нормальными тканями печени. Результаты масс-спектрометрии были подтверждены окрашиванием на соответствующие белки. Заключение. Качественный и количественный состав белков экстрацеллюлярного матрикса печеночных метастазов колоректального рака и нормальных тканей печени существенно отличается.

Aim. To investigate the composition of extracellular matrix proteins in colorectal cancer liver metastases and normal liver. Materials and Methods. Following decellularization of the extracellular matrix using a specific cocktail of detergents, we examined protein content of metastatic and normal liver tissues by means of mass-spectrometry and immunofluorescence staining. Results. Proteomic analysis revealed significant differences in the expression of extracellular matrix proteins between cancerous tissue and normal liver. Results of masspectrometry were verified by immunofluorescence staining to the relevant proteins. Conclusion. Qualitative and quantitative composition of extracellular matrix proteins substantially differs between colorectal cancer liver metastases and normal liver.

экстрацеллюлярный матриксметастазыколоректальный ракмасс-спектрометрияпротеомикаextracellular matrixmetastasiscolorectal cancermass-spectrometryproteomicsReferencesBonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014; 15(12): 786-801.Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014; 15(12): 786-801.Theocharis AD, Skandalis SS, Gialeli C, Karamanos NK. Extracellular matrix structure. Adv Drug Deliv Rev. 2016; 97:4-27.Theocharis AD, Skandalis SS, Gialeli C, Karamanos NK. Extracellular matrix structure. Adv Drug Deliv Rev. 2016; 97:4-27.Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci. 2010; 123(24): 4195-4200.Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci. 2010; 123(24): 4195-4200.Karsdal MA, Nielsen MJ, Sand JM, Henriksen K, Genovese F, Bay-Jensen AC, et al. Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol. 2013; 11(2): 70-92.Karsdal MA, Nielsen MJ, Sand JM, Henriksen K, Genovese F, Bay-Jensen AC, et al. Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol. 2013; 11(2): 70-92.Marley AR, Nan H. Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet. 2016; 7(3): 105-114.Marley AR, Nan H. Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet. 2016; 7(3): 105-114.Crapo PM, Gilbert TW, Badylak SF. An overview of tissue and whole organ decellularization processes. Biomaterials. 2011; 32(12): 3233-3243.Crapo PM, Gilbert TW, Badylak SF. An overview of tissue and whole organ decellularization processes. Biomaterials. 2011; 32(12): 3233-3243.Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, Rappsilber J, et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics. 2005; 4(9): 1265-1272.Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, Rappsilber J, et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics. 2005; 4(9): 1265-1272.Naba A, Clauser KR, Hoersch S, Liu H, Carr SA, Hynes RO. The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices. Mol Cell Proteomics. 2012; 11(4):M111.014647.Naba A, Clauser KR, Hoersch S, Liu H, Carr SA, Hynes RO. The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices. Mol Cell Proteomics. 2012; 11(4):M111.014647.Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2): 69-90.Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2): 69-90.Dimitrakopoulos L, Prassas I, Diamandis EP, Charames GS. Onco-proteogenomics: Multi-omics level data integration for accurate phenotype prediction. Crit Rev Clin Lab Sci. 2017; 54(6): 414-432.Dimitrakopoulos L, Prassas I, Diamandis EP, Charames GS. Onco-proteogenomics: Multi-omics level data integration for accurate phenotype prediction. Crit Rev Clin Lab Sci. 2017; 54(6): 414-432.David CJ, Huang YH, Chen M, Su J, Zou Y, Bardeesy N, et al. TGF-β Tumor Suppression through a Lethal EMT. Cell. 2016; 164(5): 1015-1030.David CJ, Huang YH, Chen M, Su J, Zou Y, Bardeesy N, et al. TGF-β Tumor Suppression through a Lethal EMT. Cell. 2016; 164(5): 1015-1030.Standiford TJ, Kuick R, Bhan U, Chen J, Newstead M, Keshamouni VG. TGF-B-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth. Oncogene. 2011; 30(21): 2475-2484.Standiford TJ, Kuick R, Bhan U, Chen J, Newstead M, Keshamouni VG. TGF-B-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth. Oncogene. 2011; 30(21): 2475-2484.Johansson J, Tabor V, Wikell A, Jalkanen S, Fuxe J. TGF-β1-Induced Epithelial-Mesenchymal Transition Promotes Monocyte/Macrophage Properties in Breast Cancer Cells. Front Oncol. 2015; 5; 3.Johansson J, Tabor V, Wikell A, Jalkanen S, Fuxe J. TGF-β1-Induced Epithelial-Mesenchymal Transition Promotes Monocyte/Macrophage Properties in Breast Cancer Cells. Front Oncol. 2015; 5; 3.Yang S, Chen L, Chan DW, Li QK, Zhang H. Protein signatures of molecular pathways in non-small cell lung carcinoma (NSCLC): comparison of glycoproteomics and global proteomics. Clin Proteomics. 2017; 14(1): 31.Yang S, Chen L, Chan DW, Li QK, Zhang H. Protein signatures of molecular pathways in non-small cell lung carcinoma (NSCLC): comparison of glycoproteomics and global proteomics. Clin Proteomics. 2017; 14(1): 31.Zhuang X, Zhang H, Li X, Li X, Cong M, Peng F, et al. Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1. Nat Cell Biol. 2017; 19(10): 1274-1285.Zhuang X, Zhang H, Li X, Li X, Cong M, Peng F, et al. Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1. Nat Cell Biol. 2017; 19(10): 1274-1285.Liu S, Li X, Lin Z, Su L, Yan S, Zhao B, et al. SEC-induced activation of ANXA7 GTPase suppresses prostate cancer metastasis. Cancer Lett. 2018; 416: 11-23.Liu S, Li X, Lin Z, Su L, Yan S, Zhao B, et al. SEC-induced activation of ANXA7 GTPase suppresses prostate cancer metastasis. Cancer Lett. 2018; 416: 11-23.Ye W, Li Y, Fan L, Zhao Q, Yuan H, Tan B, et al. Effect of annexin A7 suppression on the apoptosis of gastric cancer cells. Mol Cell Biochem. 2017; 429(1-2): 33-43.Ye W, Li Y, Fan L, Zhao Q, Yuan H, Tan B, et al. Effect of annexin A7 suppression on the apoptosis of gastric cancer cells. Mol Cell Biochem. 2017; 429(1-2): 33-43.Meding S, Balluff B, Elsner M, Schone C, Rauser S, Nitsche U, et al. Tissue-based proteomics reveals FXYD3, S100A11 and GSTM3 as novel markers for regional lymph node metastasis in colon cancer. J Pathol. 2012; 228(4): 459-470.Meding S, Balluff B, Elsner M, Schone C, Rauser S, Nitsche U, et al. Tissue-based proteomics reveals FXYD3, S100A11 and GSTM3 as novel markers for regional lymph node metastasis in colon cancer. J Pathol. 2012; 228(4): 459-470.Xiao M, Li T, Ji Y, Jiang F, Ni W, Zhu J, et al. S100A11 promotes human pancreatic cancer PANC-1 cell proliferation and is involved in the PI3K/AKT signaling pathway. Oncol Lett. 2017; 15(1): 175-182.Xiao M, Li T, Ji Y, Jiang F, Ni W, Zhu J, et al. S100A11 promotes human pancreatic cancer PANC-1 cell proliferation and is involved in the PI3K/AKT signaling pathway. Oncol Lett. 2017; 15(1): 175-182.Aumailley M, Bruckner-Tuderman L, Carter WG, Deutzmann R, Edgar D, Ekblom P, et al. A simplified laminin nomenclature. Matrix Biol. 2005; 24(5): 326-332.Aumailley M, Bruckner-Tuderman L, Carter WG, Deutzmann R, Edgar D, Ekblom P, et al. A simplified laminin nomenclature. Matrix Biol. 2005; 24(5): 326-332.

The authors declare that there are no conflicts of interest present.